Serum sickness with refractory nephrotic syndrome following treatment with rituximab.

about

Serum sickness with refractory nephrotic syndrome following treatment with rituximab.

Item

http://www.wikidata.org/entity/Q50154996

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Serum sickness with refractory nephrotic syndrome following treatment with rituximab.

@en

Serum sickness with refractory nephrotic syndrome following treatment with rituximab.

@nl

type

Item

label

Serum sickness with refractory nephrotic syndrome following treatment with rituximab.

@en

Serum sickness with refractory nephrotic syndrome following treatment with rituximab.

@nl

prefLabel

Serum sickness with refractory nephrotic syndrome following treatment with rituximab.

@en

Serum sickness with refractory nephrotic syndrome following treatment with rituximab.

@nl

P1476

Serum sickness with refractory nephrotic syndrome following treatment with rituximab.

@en

P2093

Kazuhide Suyama

http://www.w3.org/2001/XMLSchema#string

Mitsuaki Hosoya

http://www.w3.org/2001/XMLSchema#string

Ryo Maeda

http://www.w3.org/2001/XMLSchema#string

Shinichiro Ohara

http://www.w3.org/2001/XMLSchema#string

Yukihiko Kawasaki

http://www.w3.org/2001/XMLSchema#string

P2860

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura.

Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.

Rituximab-induced serum sickness: A systematic review.

Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.

P2888

s13730-017-0297-7

P304

69-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1007/S13730-017-0297-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29305810

http://www.w3.org/2001/XMLSchema#string

P932

5886928

http://www.w3.org/2001/XMLSchema#string